Beckman Coulter Life Sciences is taking actions in the best interests of our associates, customers, and business partners as we navigate the growing threats of the 2019 Novel Coronavirus disease (COVID-19). Learn more
Due to the mutation-rich nature of cancer cell genomes, cancer cells often produce proteins that are incomplete or flawed. Those truncated and flawed proteins, termed neoantigens, can act as a patient-specific targets for novel immunotherapies. Since every patient’s mutation load is different – every tumor’s mutation load is different – targeting these mutant proteins can mount a focused attack on the only cells in the body where the mutant protein is expressed. By directing the immune system to attack cells that express the neoantigen, off-target effects are minimized and focused destruction of tumor cells is maximized.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.